Investigation announced for Long-Term Investors in shares of Minerva Neurosciences, Inc. (NASDAQ: NERV)

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Minerva Neurosciences, Inc..

Investors who are current long term investors in Minerva Neurosciences, Inc. (NASDAQ: NERV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in Minerva Neurosciences, Inc. (NASDAQ: NERV stocks follows a lawsuit filed against NASDAQ: NERV over alleged securities laws violations. The investigation on behalf of current long term investors in Minerva Neurosciences, Inc. (NASDAQ: NERV stocks, concerns whether certain Minerva Neurosciences, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 15, 2017 and November 30, 2020, Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting, that the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States, that the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness, that the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA, that reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.